BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16288496)

  • 1. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
    J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y; Xia D; Li F; Zheng C; Xiang J
    Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells.
    Tomihara K; Kato K; Masuta Y; Nakamura K; Uchida H; Sasaki K; Tanaka T; Huang J; Hiratsuka H; Hamada H
    Gene Ther; 2008 Feb; 15(3):203-13. PubMed ID: 17989706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
    Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
    Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
    Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
    Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
    Wu JQ; Zhao WH; Li Y; Zhu B; Yin KS
    Virology; 2007 Nov; 368(2):309-16. PubMed ID: 17675129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
    Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
    Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
    Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
    Alvarez E; Moga E; Barquinero J; Sierra J; Briones J
    Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.
    Bereta M; Bereta J; Park J; Medina F; Kwak H; Kaufman HL
    Cancer Gene Ther; 2004 Dec; 11(12):808-18. PubMed ID: 15359290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
    Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
    J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
    Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
    Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine.
    Herd KA; Wiethe C; Tindle RW
    Vaccine; 2007 Jul; 25(28):5209-19. PubMed ID: 17544551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
    Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H
    Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.